IL2 and neoplasm: The emergence of targeted IL-2 delivery strategies, including immunotoxins, immunocytokines, and engineered variants, has helped mitigate these issues by improving specificity to the tumor microenvironment, reducing off-target effects, and enhancing therapeutic outcomes.